AR047154A1 - TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL - Google Patents

TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL

Info

Publication number
AR047154A1
AR047154A1 ARP040104752A ARP040104752A AR047154A1 AR 047154 A1 AR047154 A1 AR 047154A1 AR P040104752 A ARP040104752 A AR P040104752A AR P040104752 A ARP040104752 A AR P040104752A AR 047154 A1 AR047154 A1 AR 047154A1
Authority
AR
Argentina
Prior art keywords
insomnia
treatment
gaboxadol
administrandoles
daily amount
Prior art date
Application number
ARP040104752A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047154A1 publication Critical patent/AR047154A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para el tratamiento del insomnio en un paciente humano que lo necesita mediante la administracion a dicho paciente de una cantidad diaria de gaboxadol, cantidad que es efectiva para el tratamiento de insomnio. Reivindicacion 10: El uso del gaboxadol para la preparacion de un medicamento para el tratamiento del insomnio en un paciente humano, donde el medicamento se presenta en forma de dosis oral.A method for the treatment of insomnia in a human patient who needs it by administering to said patient a daily amount of gaboxadol, an amount that is effective for the treatment of insomnia. Claim 10: The use of gaboxadol for the preparation of a medicament for the treatment of insomnia in a human patient, wherein the medicament is presented as an oral dose.

ARP040104752A 2003-12-18 2004-12-17 TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL AR047154A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301877 2003-12-18

Publications (1)

Publication Number Publication Date
AR047154A1 true AR047154A1 (en) 2006-01-11

Family

ID=34684447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104752A AR047154A1 (en) 2003-12-18 2004-12-17 TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL

Country Status (17)

Country Link
EP (1) EP1720547A1 (en)
JP (1) JP2007515415A (en)
KR (1) KR20060103335A (en)
CN (1) CN1893942A (en)
AR (1) AR047154A1 (en)
AU (1) AU2004298313A1 (en)
BR (1) BRPI0415893A (en)
CA (1) CA2550610A1 (en)
EA (1) EA200600989A1 (en)
IL (1) IL176239A0 (en)
IS (1) IS8390A (en)
MX (1) MXPA06006685A (en)
NO (1) NO20063320L (en)
SG (1) SG133601A1 (en)
TW (1) TW200528098A (en)
WO (1) WO2005058313A1 (en)
ZA (1) ZA200602762B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H Acid and base salt forms of gaboxadol
MX2020002741A (en) * 2017-09-12 2020-07-21 Ovid Therapeutics Inc Use of gaboxadol in the treatment of narcolepsy.
JP2022501384A (en) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. Use of gaboxador for the treatment of Tourette's syndrome, tics and stuttering
CA3123876A1 (en) * 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
JP2023507764A (en) 2019-12-18 2023-02-27 オービッド・セラピューティクス・インコーポレイテッド Gaboxadol for therapeutic treatment of 1p36 deletion syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (en) * 1995-07-13 1997-09-25 Max Planck Gesellschaft sleeping pills
AR033896A1 (en) * 2001-05-21 2004-01-07 Lundbeck & Co As H GABOXADOL GRANULATED PREPARATIONS.

Also Published As

Publication number Publication date
CA2550610A1 (en) 2005-06-30
EA200600989A1 (en) 2006-10-27
CN1893942A (en) 2007-01-10
SG133601A1 (en) 2007-07-30
WO2005058313A1 (en) 2005-06-30
JP2007515415A (en) 2007-06-14
ZA200602762B (en) 2007-06-27
BRPI0415893A (en) 2007-01-09
IS8390A (en) 2006-03-30
KR20060103335A (en) 2006-09-28
EP1720547A1 (en) 2006-11-15
NO20063320L (en) 2006-07-18
AU2004298313A1 (en) 2005-06-30
TW200528098A (en) 2005-09-01
MXPA06006685A (en) 2006-08-23
IL176239A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1116727T1 (en) Multiple Sclerosis Treatment With LAQUINIMOD
NO20055880L (en) Memantine oral dosage forms
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
AR050418A1 (en) HER ANTIBODY FIXED DOSAGE
PE20170302A1 (en) USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE
AR065580A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
ECSP045069A (en) USE OF FLIBANSERINE IN THE TREATMENT OF SEXUAL DISORDERS
JP2006501240A5 (en)
BRPI0513200A (en) use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
CO6150188A2 (en) USE OF TEENCTEPLASA TO TREAT AN ACUTE ISCHEMICAL ICTUS
AR065579A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR090885A1 (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
AR054249A1 (en) TREATMENT OF SKIN CONNECTIVE TISSUE DISEASES
AR065581A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR065139A1 (en) MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS
AR047154A1 (en) TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL
AR027394A1 (en) USE OF MIRTAZAPINE FOR THE TREATMENT OF SOIL DISORDERS
ECSP066836A (en) PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETROSIS
DK1675611T3 (en) Therapeutic uses for C-peptide
NZ597675A (en) Medicament for the long term nsaid use
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
AR061046A1 (en) MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal